Trial Profile
Dolutegravir Impact on Residual Replication: Dolutegravir Intensification Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms DIORR
- 07 Mar 2018 Primary endpoint (Level of residual HIV replication in circulating CD4+ T cells) has not been met as per the results presented at the 25th Conference on Retroviruses and Opportunistic Infections.
- 07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections
- 16 Nov 2017 Status changed from active, no longer recruiting to completed.